1. Home
  2. MFIC vs PHVS Comparison

MFIC vs PHVS Comparison

Compare MFIC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFIC
  • PHVS
  • Stock Information
  • Founded
  • MFIC 2004
  • PHVS 2015
  • Country
  • MFIC United States
  • PHVS Netherlands
  • Employees
  • MFIC N/A
  • PHVS N/A
  • Industry
  • MFIC Finance/Investors Services
  • PHVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MFIC Finance
  • PHVS Health Care
  • Exchange
  • MFIC Nasdaq
  • PHVS Nasdaq
  • Market Cap
  • MFIC 1.4B
  • PHVS 862.3M
  • IPO Year
  • MFIC 2004
  • PHVS 2021
  • Fundamental
  • Price
  • MFIC $12.96
  • PHVS $16.67
  • Analyst Decision
  • MFIC Hold
  • PHVS Strong Buy
  • Analyst Count
  • MFIC 5
  • PHVS 5
  • Target Price
  • MFIC $14.25
  • PHVS $41.60
  • AVG Volume (30 Days)
  • MFIC 692.6K
  • PHVS 51.4K
  • Earning Date
  • MFIC 05-06-2025
  • PHVS 05-07-2025
  • Dividend Yield
  • MFIC 11.72%
  • PHVS N/A
  • EPS Growth
  • MFIC N/A
  • PHVS N/A
  • EPS
  • MFIC 1.27
  • PHVS N/A
  • Revenue
  • MFIC $301,782,000.00
  • PHVS N/A
  • Revenue This Year
  • MFIC $18.25
  • PHVS N/A
  • Revenue Next Year
  • MFIC $1.66
  • PHVS N/A
  • P/E Ratio
  • MFIC $10.23
  • PHVS N/A
  • Revenue Growth
  • MFIC 9.13
  • PHVS N/A
  • 52 Week Low
  • MFIC $12.26
  • PHVS $14.14
  • 52 Week High
  • MFIC $16.36
  • PHVS $26.57
  • Technical
  • Relative Strength Index (RSI)
  • MFIC 38.63
  • PHVS 52.81
  • Support Level
  • MFIC $12.35
  • PHVS $14.49
  • Resistance Level
  • MFIC $13.07
  • PHVS $17.99
  • Average True Range (ATR)
  • MFIC 0.35
  • PHVS 1.34
  • MACD
  • MFIC -0.12
  • PHVS 0.22
  • Stochastic Oscillator
  • MFIC 27.35
  • PHVS 65.71

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: